





OBJECTIVES

- Review the QMP timeline
- Discuss activities 2017/18:
 - Quality Assurance
 - Quality Improvement
 - Quality Reporting
 - Clinical Leadership
 - Other activities
- Update on activities for 2018/19

IMPLEMENTATION PRIORITIES



Provincial Standards: Ensure consistency of quality practices



Quality Reporting: Release facility, regional and provincial reports




Clinical Leadership: Establish and engage three levels of clinical leadership (provincial, regional and facility)




Quality Improvement Resources: Develop and share quality improvement resources

TIMELINE AND ACTIVITIES 2013- 17



Timeline and Activities 2017-18



Pathology QMP Update: Quality Assurance

- Guidance document on categorization of discordance, based on clinical impact has been developed and disseminated to facility leads
- Standards Working Group:
 - Defining next group of standards
 - Collaboration with Path2Quality (P2Q) related to standards
 - Monitoring standards discussion

Guidance document on categorization of discordance

• Why?

- Requirement to classify, document and review discordances
- 2017 QMP survey, CPSO facility needs assessment, discussions with regional and facility leads - consistent need for standardized terminology

Methodology:

- Literature review and reference material from key organizations (CAP, Royal College of Pathology UK)
- Environmental scan from Ontario facilities

Guidance document on categorization of discordance

Principles:

- Sufficiently broad so that it can be adopted/used in facilities with little changes/modifications to existing categorizations
- Emphasis on impact to patient care
- Limited role for assigning a numerical role for discordance at system level however Lab Directors/Chief may find this of value within a facility
- Etiology of discordance equally if not more importance for quality improvement
- Impact to patient care may not be known category of Cannot be Determined
- Accountability of how reviews of discordance are handled responsibility of individual facility
- Living document for reassessment and updates over time

Guidance document on categorization of discordance

A. Near miss - no patient impact or potential for patient impact due to timely intervention.

Example:

Discordance at intradepartmental consultation detected before sign-off.

B. Discordance with no or minor patient impact - did not trigger an irreversible surgical procedure, harmful therapeutic intervention or result in serious complication or morbidity. Example:

Intraoperative consultation of an ovarian lesion as benign A and changes to benign B

C. Discordance with major patient impact - loss of life, limb, major organ or serious complication/morbidity due to inappropriate or delayed therapy due to discrepant diagnosis. Example:

Tissue contaminant on a small biopsy results in misdiagnosis of cancer and an unnecessary surgery

D. CND-Can Not Determine Patient Impact - due to lack of clinical follow-up or clinical information. These cases should be documented as patient impact may become apparent at a later date and they may be important for facility and/or individual quality improvement.

- Communities of Practice (CoP):
 - Pathology Laboratory Information System (LIS) CoP
 - Maximize use of the Meditech LIS QA system, by sharing practices to track quality indicators within Region 3, 4, 5 and 6.

Paediatric Pathology CoP:

- Focus on quality within paediatric pathology, including comparing practices related to standards, guidelines and best practice
- Promote quality practice in paediatric pathology

- Facility Lead (FL) training needs assessment completed found high degree of willingness to participate in FL activities, though training and resources are needed to:
 - Develop leadership and communication skills to approach fellow pathologists
 - Help facility leads identify discordant results and approach pathologists if needed
 - Help facility leads to engage and learn from each other
 - Provide more efficient data collection and reporting methods (e.g. better IT solutions), to facilitate the development of improvement plans and adoption of appropriate Partnership standards

- Quality Improvement Consultation Project undertaken to understand integration of the QMP reports and review three factors for success in QI:
 - QI Leadership & Organizational Readiness
 - Workforce Capacity & Capability
 - QI Knowledge & Initiative Results
- Pathology was found to have the highest in overall QI maturity and capability across all three success factors
- However, numerous recommendations focused on the following themes:
 - Quality Improvement Resources
 - Communities of Practice
 - QI Foundations Training
 - Facility Leadership Roles and Facility Engagement
 - Quality Reporting

 Training expansion under development, e.g., QI, Facilitated Feedback

Pathology Provincial QIP

Goals:

- 1. Increase provincial uptake of the foundational prioritized standards (Standards 1 to 3) to achieve target.
- 2. Develop the processes and lay the foundation to go forward with a provincial turnaround time (TAT) validation study in 2019.

Improvement Measures:

Quality Measure	Quality Dimension	2017 Reported Compliance	2018 Reported Compliance	Target/Goal (December 2019)
Compliance to prioritized Standard 1: Laboratories shall have a Pathology Professional Quality Management committee.	Effectiveness	75%	Pending	90% * Smaller labs may have a harder time establishing a Pathology Professional Quality Management committee.
Compliance to prioritized Standard 2: Laboratories shall have a professional quality management plan.	Effectiveness	82%	Pending	100%
3. Compliance to prioritized Standard 3: Laboratories shall have a documented policy and related processes and procedures for the classification of report defects, discrepancies, discordances, errors and their investigation and resolution.	Effectiveness Accuracy	78%	Pending	100%

Improvement Activities:

Planned Improvement Initiative	Improvement Method	Measure for Success (Target/	
Pathology QMP will collect and collate feedback received from regional and/or facility leads about barriers to the	Feedback provided by all regional leads in the form of regional lead engagement templates.	Goal) Feedback received and collated by October 2018.	
implementation of Standards 1 to 3. This will also include collating feedback from the 2018 survey.	b. 2018 survey data will be used to identify barriers to implementation.	Barriers identified by December 2018.	
	c. Identify quality improvement opportunities based on the 2018 survey results and feedback from regional leads.	Identity improvement opportunities by January 2019.	
Pathology QMP to develop education material related to the standards implementation.	Update pathology standards toolkit with reference material.	Post updated pathology standards toolkit with reference material in July 2018.	
	b. Develop education modules related to quality improvement plans.	Educational modules developed by August 2018.	
	c. Host a webinar/discussion board on LearnQMP related to quality improvement plans.	Host webinar/ discussion board in fall 2018.	
Pathology QMP to complete background work and logistics for TAT validation study.	TAT data to be provided to all facilities for validation. A more detailed record level review of data will be conducted for facilities as required based on the TAT data validation results.	TAT validation report to be distributed to facilities in February 2019.	

Pathology QMP Update: Quality Reporting

- 2018 Survey completed 54/55 facilities responded.
- Pathology QMP report release targeted for the end of Nov 2018
- Turnaround time (TAT) validation planned for January 2019; involves two components:
 - Data quality assessment
 - Record level review, may be required
- Lack of Pathology QMP data collection strategy is a barrier for further indicator work

Pathology QMP Update

Clinical Leadership:

- Regional Lead recruitment underway
- Vision for Pathology Quality Management Leadership process for streamlining and establishing a unified clinical leadership structure

Other Initiatives / Work:

- Summer update and Pathology Toolkit distributed on Aug 20th
- Collaboration with Breast Imaging and Breast Disease Pathways Group around indeterminate lesions - ongoing
- Collaboration with Colonoscopy QMP:
 - Recommendations for polypectomy requisitions and reporting is finalized
 - Education around these recommendations to occur in both the Pathology and Colonoscopy QMP

